New long-term TEGSEDI safety and efficacy data featured as an oral presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

NEURO-TTR phase 3 open-label extension study showed TEGSEDI® (inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy

The release as fetched from its publisher. ionis.com ↗